Use of Closed System Transfer Devices (CSTDs) with Protein-Based Therapeutic Drugs-A Non-Solution for a Non-Problem?

Autor:	Fast J; Pharmaceutical Development, F. Hoffmann-La Roche Ltd. CH-4070 Basel, Switzerland. Electronic address: jonas.fast@roche.com., Christian T; Process Development, Amgen, Thousand Oaks, CA, USA., Crul M; Amsterdam University Medical Center, Department of Clinical Pharmacology and Pharmacy, Amsterdam, the Netherlands., Jiskoot W; Division of BioTherapeutics, Leiden University, the Netherlands; Coriolis Pharma, Martinsried, Germany., Nejadnik MR; Department of Pharmaceutical Sciences & Experimental Therapeutics, College of Pharmacy, University of Iowa, Iowa City, IA, USA., Medina A; Dosage Form Design and Development, AstraZeneca, Gaithersburg, MD, USA., Radwick A; United States Pharmacopeia, Rockville, MD, USA., Sreedhara A; Pharmaceutical Development, Genentech, South San Francisco, CA, USA., Tole H; Occupational Health, Hygiene &Toxicology, Genentech Inc., Little Falls, NJ, USA.
Jazyk:	angličtina
Zdroj:	Journal of pharmaceutical sciences [J Pharm Sci] 2024 Feb; Vol. 113 (2), pp. 298-305. Date of Electronic Publication: 2023 Nov 19.
DOI:	10.1016/j.xphs.2023.11.014
Abstrakt:	Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this article.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu